Myriad genetics

Investor Day 2023

September 19, 2023

Forward-looking statements and Non-GAAP financial measures

Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company.

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research. The reported number of patients in Epic's network (250M) and clinicians (2,000+) in Flatiron's network was provided by Epic and Flatiron, respectively.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation.

Today's Agenda

Paul J. Diaz PRESIDENT AND CHIEF EXECUTIVE OFICER		**Well positioned to drive accelerating growth and profitability** Focus on commercial execution and innovation
Marc Leighton SVP, PRODUCT MANAGEMENT		**Addressing large underpenetrated markets with differentiated products and services** Expanding genetic testing in markets affecting millions of lives
Mark Verratti CHIEF COMMERCIAL OFFICER		**Executing to win** Expanding commercial sales and marketing capabilities to increase access to genetic testing and drive growth
Nicole Lambert CHIEF OPERATING OFFICER		**Enhancing core lab capabilities** Supporting growth, productivity, and innovation —Lab of the Future
Dale Muzzey, Ph.D. CHIEF SCIENTIFIC OFFICER		**What's next** Innovating and elevating our product pipeline
Katie Johansen Taber, Ph.D. VP, CLINICAL PRODUCT RESEARCH		**Closer look at clinical programs and real-world evidence** Robust pipeline of clinical studies
Bryan Riggsbee CHIEF FINANCIAL OFFICER		**Delivering shareholder value** Long-term growth and profitability

Paul J. Diaz

PRESIDENT AND CHIEF EXECUTIVE OFFICER

Well positioned to drive accelerating growth and profitability

Myriad genetics®

Myriad genetics

Health. Illuminated.

Revealing the power of genetic science – for everyone

Mission

We advance health and well-being for all, empowering every individual by revealing the answers inside each of us.

Vision

As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease.



Moving from transformation to innovation and growth

Myriad Genetics at-a-glance

A leader in genetic testing
Established franchises in hereditary cancer, pharmacogenomics, and prenatal testing

30+ years of scientific and commercial achievements
1,000+ scientific publications and counting

42,000+
active ordering healthcare providers

72.5
net promoter score[1]

~2,600
employees[1]

10%+ annual revenue growth for third consecutive quarter[2]
Commercial execution driving volume growth; price stability

Market-leading gross margins; healthy balance sheet

Innovation in '24 and beyond
Expect to launch multiple differentiated tests in prenatal and oncology through 2026

1. As of year end 2022
2. As of second quarter 2023 and excludes contribution from change of revenue estimates

Second quarter operating and financial highlights

Double-digit revenue growth despite payor headwinds

+10%

revenue growth YOY*

Third consecutive quarter achieving double-digit revenue growth.*

Testing volume growth driven across each Business Unit

+17%

volume growth YOY**

YOY volume growth by unit:

+23% in Pharmacogenomics

+14% in Women's Health**

+11% in Oncology

Positive Trend in Gross Margin and Adj. OpEx

Non-GAAP gross margin of 69% **increased 130 basis points** from Q1 '23.***

Adjusted operating expenses **declined $11.1 million** from Q1 '23 to $133.4 million.***

New credit facility adds financial flexibility; on-track to achieve positive adjusted operating cash flow

Established new $90M asset-based credit facility.

Generated $5.9M in adjusted operating cash flow in Q2 '23.

Reaffirm adjusted profitability and positive adjusted operating cash flow Q4 '23 targets.

* Excluding contribution from change of revenue estimates of $11.7M in Q2 '22 and an immaterial amount in Q2 '23
** Excluding contributions from the SneakPeek® Early Gender DNA test
***Gross margin and adjusted operating expenses are non-GAAP measures. See Appendix to this presentation for the definitions and a reconciliation to the nearest GAAP measure.

Pillars of long-term growth and profitability

Science and innovation

Top-tier science delivering products that are clinically validated and demonstrate proven utility (quality, access and cost) in real world clinical settings

Elevated customer engagement and commercial execution

Strong digitally enabled commercial platform

Technology led operations

Automated, scalable, and cost-effective laboratory operations and technology platform

Scalable administrative support services

Advanced regulatory, reimbursement, and revenue cycle capabilities

Well positioned to take advantage of future market opportunities

Revenue growth expected to accelerate 10%+ in '24 – '26	Goal to generate $1B+ in revenue by 2026
Right to win with core products driving market share gains	Enhanced commercial execution generating double-digit volume growth as adoption rates and competitive position improves
Pipeline addresses large growth markets	Robust and differentiated product pipeline opens access to incremental multi-billion-dollar markets
Operating leverage, profitability, and positive cash flow	Strength of business model, technology platform and enhanced laboratory capabilities to drive operating leverage, profitability and cash flow in 2024–2026
Capital deployment	Disciplined capital deployment; continue to invest in high ROI opportunities within core channels

Diversified portfolio within large, fragmented, actionable markets

	Oncology					Women's Health		PGx
	AFFECTED HCT + GERMLINE	TUMOR PROFILING[3]	MRD	HRD[2]	UROLOGY	PRENATAL	UNAFFECTED HCT	PGx
Actionable Market Opp.[1]	$1.2B	$500M	$20B+	$350M	$600M	$2.3B	$3B	$5B
Market Penetration	~65%	~45%	<5%	~40%	~35%	~50%	<15%	~15%
Myriad Products	MyRisk BRAC CDx	Precise Tumor *Precise Liquid* *(pipeline)*	*Precise MRD* *(pipeline)*	MyChoice CDx	Prolaris	Foresight Prequel FirstGene	MyRisk BRAC CDx	GeneSight

>$30B
of actionable market opportunity

<40%
average market penetration across all categories

<20%
of market share concentrated among Top 3 players

Myriad holds
Top 3 position
in 6 out of 7 active product categories

1: Actionable market indicated against cancers of commercial focus
2: In ovarian, breast, prostate, pancreatic cancers only
3: Reflective of IHC partnership
Data as of 2022 from third party global consulting firm and internal estimates

Myriad genetics®

Marc Leighton

SVP, PRODUCT MANAGEMENT

Addressing large underpenetrated markets with differentiated products and services

Myriad genetics®

Improved product management strategy

Enterprise alignment to deliver on product strategy and help deliver sustainable growth

Data-driven, user-centric, and research-oriented
*...**Informs** roadmap strategy*

Relentless pursuit of improving experiences
*...**Ease** of use critical*

Set and communicate the product vision
*...**Align** the organization to a shared strategy*

Invest for customer value creation and Myriad sustainability
*...**Balance** innovation with scalability*

Enable our product vision through intentional organizational design



Myriad genetics®

3 focus areas: Women's Health, Oncology, and Pharmacogenomics

	Women's Health	Oncology	Pharmacogenomics
Business	A leader in health and wellness with differentiated genetic insights for women of all ancestries, assessing cancer risk and offering prenatal solutions.	Clarifying cancer treatment with genetic and genomic insights and companion diagnostic tests that are designed to work with corresponding drugs and treatments.	Using genetic insights to help physicians understand how genetic alterations impact patient response to antidepressants and other drugs.
Actionable Market Size*	$5 Billion	$23 Billion	$5 Billion
Target Customer	OB/GYN Maternal Fetal Medicine Primary Care Genetic Counselor	Oncologist Surgeon Urologist Genetic Counselor	Psychiatrist Primary Care Nurse Practitioner/Physician Assistant
	MyRisk™ Hereditary Cancer Test with RiskScore® for all ancestries Foresight® Carrier Screen SneakPeek® 2024E Launch FirstGene™ Comprehensive Prenatal Screen Prequel® Prenatal Screen	MyRisk™ Hereditary Cancer Test Prolaris® Prostate Cancer Prognostic Test EndoPredict® Breast Cancer Prognostic Test Precise™ Liquid Molecular Profile Test MyChoice® CDx Myriad HRD Companion Diagnostic Test BRACAnalysis CDx® Germline Companion Diagnostic Test Precise™ Tumor Molecular Profile Test Precise™ MRD Minimal Residual Disease Monitoring	GeneSight® Mental Health Medication Test

*Source: Based upon company and third-party estimates and industry research

Myriad genetics®

MyRisk helps identify patients at risk of hereditary cancer

MyRisk®
Hereditary Cancer Test

A hereditary test that evaluates patient risk for **11** cancer indications based on **48** clinically significant genes and recommended by the **National Comprehensive Cancer Network** (NCCN) to assess *BRCA* mutations and eligibility for select treatment protocols

- MyRisk® hereditary cancer panel
- Clinical and cancer history analysis
- RiskScore for breast cancer



More than 50% of unaffected patients tested with MyRisk® with RiskScore ® will qualify for a change to their medical management.

*Source: Myriad Internal Data based on OBGYN and Primary Care Settings, 2022
**Source: Myriad internal data based on MyRisk tests reported between 9/1/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.

Myriad genetics®

MyRisk addresses the needs of large and growing markets

MyRisk®
Hereditary Cancer Test

Unaffected Market – Hereditary Screening

Actionable market size (US only)	Market penetration	Market growth	MYGN market share
~$3B	15%	High single digits	30% - 35%

Affected Market – Germline Screening

Actionable market size (US only)	Market penetration	Market growth	MYGN market share
~$1.2B	65%	Mid single digits	~20%





Data as of 2022, source: Third party global consulting firm
*In cancers of focus
All numbers shown are 2022 estimates

Significant opportunity to accelerate MyRisk growth across Women's Health, Imaging, Oncology and Urology

MyRisk®
Hereditary Cancer Test

Roadmap highlights

2023-2024

- MyRisk patient portal
- RiskScore Tyrer-Cuzick update
- MyRisk Medical Management Tool Enhancements
- RiskScore studies
- Breast Cancer Risk Assessment Program

2025

- Panel Expansion | WES (whole exome sequencing)
- BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands



Myriad genetics®

GeneSight is the market-leading PGx test

GeneSight®
Mental Health Medication Test

GeneSight helps physicians understand how patients will respond to medications used to treat depression, anxiety, ADHD, and other psychiatric conditions.

2 Million +
people have taken the GeneSight test

7 Clinical Studies
published in peer reviewed journals, including independent randomized controlled trial in *JAMA*



GeneSight® Psychotropic
Pharmacogenomic Test

genesight

Patient, Sample
Date of Birth: 7/22/1984
Clinician: Sample Clinician

Order Number: 3740219
Report Date: 1/11/2022
Reference: 145CIP

Questions about report interpretation?
Contact our medical information team:
855.891.9415 | medinfo@genesight.com

Antidepressants

Use as Directed	Moderate Gene-drug Interaction		Significant Gene-drug Interaction	
desvenlafaxine (Pristiq®)	**trazodone** (Desyrel®)	1	**selegiline** (Emsam®)	2
levomilnacipran (Fetzima®)	**venlafaxine** (Effexor®)	1	**mirtazapine** (Remeron®)	1,6
vilazodone (Viibryd®)	**fluoxetine** (Prozac®)	1,4	**sertraline** (Zoloft®)	2,4
	bupropion (Wellbutrin®)	1,6	**amitriptyline** (Elavil®)	1,6,8
	citalopram (Celexa®)	3,4	**clomipramine** (Anafranil®)	1,6,8
	escitalopram (Lexapro®)	3,4	**desipramine** (Norpramin®)	1,6,8
			doxepin (Sinequan®)	1,6,8
			duloxetine (Cymbalta®)	1,6,8
			imipramine (Tofranil®)	1,6,8
			nortriptyline (Pamelor®)	1,6,8
			vortioxetine (Trintellix®)	1,6,8
			fluvoxamine (Luvox®)	1,4,6,8
			paroxetine (Paxil®)	1,4,6,8

Ordered by tens of thousands of clinicians to inform medication selection and dosing

Measures multiple genomic variants for each individual to categorize medications and provide clinical considerations

Market leading psychiatric PGx test and the only test backed by seven clinical studies published in peer-reviewed journals

Helps physicians and patients avoid multiple medication trials by informing which medications may require dose adjustments, be less likely to work, or have increased risk of side effects.

Myriad genetics®

Strong commercial execution driving significant volume growth, last twelve months

GeneSight®
Mental Health Medication Test

Actionable market size (US only)*	Market penetration*	Market growth*	MYGN market share*
~$5B	15%	Mid teens	55-60%

Roadmap highlights

2023-2024
- Psych 4.2
- Indication Expansion
- Health Economic Outcome Research (HEOR) study

2025
- Postpartum Clin Dev Protocol & Study

*Data as of 2022, source: Third party global consulting firm and internal estimates

This study used data from the Optum Labs Data Warehouse, composed of de-identified administrative claims data for both commercially insured and Medicare Advantage enrollees. The claims data were linked on a de-identified basis with PGx test results.

GeneSight test volume

Figures in thousands



	Q3 '22	Q4 '22	Q1 '23	Q2 '23
YOY Growth	+34%	+22%	+31%	+23%

Myriad genetics®

In localized prostate cancer, Prolaris® is a market leading biomarker test to help determine optimal treatment planning

Prolaris®
Prostate Cancer Prognostic Test

Prolaris utilizes **two validated thresholds** to identify men that are **safe for active surveillance,** candidates for **a single type of therapy,** and those who would benefit from **multiple therapeutic options**

LOWER PROLARIS SCORE ← → HIGHER PROLARIS SCORE

Active surveillance	Single-modal treatment	Multi-modal treatment
Men safe for active surveillance	Men not safe for active surveillance → candidates for single-modal therapy	Men not safe for single-modal therapy → candidates for multi-modal treatment



RESEARCH VALIDATION

In a head-to-head study*, Prolaris identified **>86% of low-risk** patients as candidates for active surveillance aligns with NCCN guidelines

*Hu, J. C., et al. Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. JCO Precision Oncology, 2018; 1-15 doi:10.1200/po.18.00163

Myriad genetics®

Strong runway for Prolaris with an opportunity to capture more market share with compelling updates

Prolaris®
Prostate Cancer Prognostic Test

Actionable market size (US only)*	Market penetration*	Market growth*	MYGN market share*
~$600M	35%	Low teens	~40%

Roadmap highlights

2023-2024
- ARR (Absolute Risk Reduction) report
- Node Guidance report update
- Pathology AI
- Publish 3-yr Metastasis study

2025
- 15-20 yr. DSM report update
- Prolaris Post-RP launch

*Data as of 2022, source: Third party global consulting firm

Prolaris test volume

Figures in thousands



Myriad genetics®

Comprehensive prenatal care with differentiated products and reliable technology

Prequel®

Prenatal Screen

Shown to deliver accurate answers to patients regardless of age, ancestry, or body mass index—the Prequel Prenatal Screen with AMPLIFY™ helps determine a pregnancy's risk for a variety of chromosomal conditions.

- AMPLIFY fetal fraction amplification delivers first-time accurate results to >99.9% of patients at 10 weeks.*
- Industry-low screening failure rate** reduces the chance of repeat screens or unnecessary, invasive diagnostics such as amniocentesis.

Foresight®

Carrier Screen

Foresight identifies couples at risk of passing down serious, inherited conditions to their children to guide informed planning, preparation and care.

- Highest published at-risk couple detection rate for serious conditions (1 in 22 couples)***
- >99% detection rate for the vast majority of genes in couples across all ancestries

*Welker et al. High-throughput fetal fraction amplification increases analytical performance of noninvasive prenatal screening. Genet Med 23, 443–450 (2021).
** Hancock et al. 2020. Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate. Ultrasound Obstet Gynecol. 2020 Sep;56(3):422-430.
***Hogan et al. Validation of an Expanded Carrier Screen that Optimizes Sensitivity via Full-Exon Sequencing and Panel-wide Copy Number Variant Identification. Clinical Chemistry 2018;doi:10.1373/clinchem.2018.286823.

A market that continues to grow with potential tailwinds from guideline expansion

Prequel®
Prenatal Screen

Foresight®
Carrier Screen

	Actionable market size (US only)*	Market penetration*	Market growth*	MYGN market share*
PREQUEL	~$1.3B	45-55%	Low single digits	Low-to-mid teens
FORESIGHT	~$950M	40-50%	Low single digits	Mid teens

Roadmap highlights

2023-2024
- Foresight on NovaSeq
- FirstGene Launch
- Various Prequel studies
- Foresight Panel Expansion

Prenatal test volume ex/ SneakPeek

Figures in thousands



	Q3 '22	Q4 '22	Q1 '23	Q2 '23
YOY Growth	+0%	(1%)	+12%	+12%

*Data as of 2022, source: Third party global consulting firm

Myriad genetics®

MyChoice CDx is the only FDA-approved, ASCO-endorsed test for HRD in ovarian cancer

MyChoice® CDx
Myriad HRD Companion Diagnostic Test

Actionable market size (US only)*	Market penetration*	Market growth*
~$300M	<10%	Mid teens

Roadmap highlights

Breast and Prostate indication expansion (2025 – 2026)

1 in 2 patients with ovarian cancer are HRD+



1 in 4 HRD+ patients have a *BRCA1/2* mutation



Of ovarian cancer patients who are HRD+
15% Somatic
10% Germline



*Data as of 2022, source: Third party global consulting firm, includes indications for Breast, Ovarian, Pancreatic, Prostate

Myriad genetics®

Myriad Genetics roadmap snapshot



Mark Verratti

CHIEF COMMERCIAL OFFICER

Executing to win

30 years and counting:
A commitment to uncovering breast cancer risk

A decade of providing patients with hereditary cancer risk

10 years since the launch of MyRisk

Comprehensive risk assessment to provide 5-year and lifetime cancer risk

Density + Risk Model + Genetics to provide 5-year Breast Cancer risk and lifetime hereditary risk of 11 different cancers

Impactful short and long-term medical management

More than 50% of all patients who take a MyRisk test get a medical management change with assistance of counseling services provided by 50+ live genetic counselors



Myriad genetics®

Building hereditary cancer testing awareness among consumers

TODAY ON THE SHOW SHOP WELLNESS PARENTS TODAY all day

DISEASE

Cancer is rising in young people. This little-known syndrome may be one reason why

Having Lynch syndrome makes it more likely to be diagnosed at a young age with several different types

Singleton discovered he had Lynch syndrome after undergoing a test from Myriad Genetics. Suddenly, the premature cancer deaths of his relatives made sense.

muscle — until the pain started intensifying. Then he noticed blood in his stool, started getting acid reflux and developed fatigue so bad that he went to bed by 6 p.m.

TODAY

MORNING NEWS NOW

NBC NEWS DAILY

verywell health

KATU 2 abc | WSBT 22 | 4 EL PASO · LAS CRUCES

14 airings
Sinclair Broadcast Group



_Source: Myriad Genetics Survey

_Myriad Genetics Cancer Risk Survey



verywell health | Health A-Z | Prevention & Treatment | Health Care | News | Tools & Resources | About Us

"When you have family history that meets guidelines for genetic testing, genetic testing is a good screening tool to use before 'traditional' mammogram age," Melissa Gonzales, president of women's health at Myriad Genetics, told Verywell. Women using Myriad's genetic testing receive guidance on whether early screening or extra screening is advisable. "Genetic testing can assess your risk based on familial and personal risk factors to identify if a patient is warranted for a medical management change, such as earlier mammograms."

Our transformation journey takes us on a course of sustainable growth and profitability



Sales
Commercial focus primarily through sales channel

Marketing
Growing our in-house marketing functionality across all parts of the business

Enablement
Accelerating the existing foundation with high quality data and technology stack to deliver on our growth

Data
Becoming a data-driven organization that can orchestrate customized experiences through data

Insights
Build on a growth-driven model that moves past foundational strengths to unlock new opportunities through insights and customer experience focus

A strong scalable commercial team – unified in a singular goal

ENTERPRISE COMMERCIAL STRATEGY

- Product management
- Market intelligence
- Sales enablement
- Customer targeting

ENTERPRISE EXECUTION

- Public relations
- Digital marketing
- Brand
- Measurement & reporting

COMMERCIAL BUSINESS UNIT

- Field sales
- Internal sales
- Marketing
- Medical

COMMERCIAL TEAM MEMBERS

59 Enterprise

265 Women's Health

180 Oncology

181 Pharmacogenomics

Our commitment and dedication to patients and the providers that treat them come from a

685 person team*

*as of August 2023

Operations and commercial enablement bring about efficiency and analytics to help the organization scale to meet demand

96% Of sales team using sales enablement tools

77% Of our salesforce has more than 2 years of service

110% Salesforce 1H 2023 Quota Achievement

An-always on training model to offer continuous education and training for the sales force in an ever-changing, dynamic market

Customer segmentation through data analytics platform to drive efficient, actionable growth in the field

Marketing
Telling a vibrant story of how we deliver value with authenticity across channels

Insights
Identifying opportunities through a constant focus on our customers, patients and their needs

Operations & Enablement
Creating the right operating model for sales with a solid foundation of technology-enabled infrastructure

Product Management
Using customer insights to develop and enhance our product portfolio

Commercial strategy and priorities

- Growth driven by strength of the complete portfolio
- Exploring adjacent channels to meet the patient and provider where they are
- Accelerating the use of data-driven insights for targeted growth
- Building a sustainable and profitable business across the portfolio with clinically-minded innovation

Myriad Commercial

Accelerating integrations

Creating a **friction-free experience** for **providers & patients** to retain customers and limit churn

Driving depth in account

Seeing wins with driving **double and triple-plays** with accounts, proving the value of our portfolio of products at each call point

Large account focus

A dedicated National Accounts team focused on large accounts

Channel Expansion

Entering new channels to meet patients and providers where they are, with products that deliver value

EMR integration streamlines workflows, rapidly expanding test volume

Accelerating integrations

Number of incremental new provider sites integrated with EMR



* Year-to-date as of June 30, 2023

** Measured from average integration 90 days pre-integration to 90 days post-integration.

flatiron

Epic

athenahealth

eClinicalWorks

nextgen healthcare

practicefusion

Greenway Health

AdvancedMD

Key EMR partnerships will enable high-volume testing across the portfolio in large health systems in Women's Health and Oncology

Accelerating integrations

Speed
Turnkey integrations reducing time-to-connection from months to weeks

Reimbursement
Bi-directional data exchange reduces exceptions and automates workflows

Comprehensive patient care
Seamlessly integrates genetics insights for tailored, personalized care

Myriad genetics + Epic

Myriad genetics + flatiron

Accelerator for Women's Health

250 million patients in the network

- Turnkey integration with Epic's Aura network
- MyRisk, Prenatal, Genesight available now
- Full-scale ramp expected in Q4 '23

Oncology focus

2,000+ clinicians nationwide

- Full suite of oncology products
- Detailed variant data
- Expect to launch in 2024

Automated end-to-end workflow to enable frictionless testing at scale for large health systems and physician groups

Large account focus

Myriad genetics + SimonMed Imaging See Tomorrow Today® + Lifepoint Health

Patient In-take & Counseling

Myriad AI-enhanced consumer chatbot
engage, educate 10x higher test conversion

MyGeneHistory
streamlines patient intake

Patient Education Genetic Counseling
value of testing

Myriad Cost Estimator
determine patient out-of-pocket costs

Laboratory Testing & Resulting

Provider Portal Ordering
small/medium-sized practices

Laboratory Genetic Testing

Provider Portal Resulting
physician access to genetic test results

Patient Portal
patient access to genetic test results

EMR Ordering
larger healthcare systems

EMR Resulting
larger healthcare systems

Patient Care

Tyrer Cusik and MyRisk Management
breast cancer risks and care recommendations

Clinical Care/ Management Support

The imaging channel helps Myriad unlock Hereditary Cancer Testing market share from patients who fall through traditional channels

SimonMed *See Tomorrow Today*

Onsite WOMEN'S HEALTH

Lifepoint Health

American College of Radiology and Society of Breast Imaging have called for all women 30 years of age and above to have their risk assessment completed[1]

New FDA "dense breast" reporting requirement going into effect in September 2024

Channel Expansion

Annualized Opportunity

100% Mammograms (Annual)

32% meet testing criteria
per Loving et al. (2020)[2]

30% opt-in to testing[3]
⊕ 8% positive ✱ 46% high risk

>50% w/ change in risk management[3]

⊕ Mutation positive ✱ High-risk negative

1. https://www.sbi-online.org/Portals/0/Position%20Statements/2018/New-2018-BCS-Guidelines.pdf
2. Loving, V. et al. A Breast Radiology Department-operated, Proactive Same-day Program Identifies Pathogenic Breast Cancer Mutations in Unaffected Women. Acad Radiol. 2022 Jan;29 Suppl 1:S239-S245
3. Myriad Internal Data (MMT For Unaffected Patient Population in the WH Space)

Entering the consumer-initiated testing segment with growing brand awareness

Channel Expansion

SneakPeek® | Walgreens

- Predicts babies' fetal sex as early as 6 weeks of pregnancy with 99% accuracy
- >970,000 tests to date (across all channels)
- Now available in 3,450 stores

- **78% of US population lives within 5 miles of Walgreen's store**
- **10M daily customers in its stores and online**
- **Top retailer for home pregnancy tests**



Meeting patients **where they are** with a comprehensive portfolio

Nicole Lambert

CHIEF OPERATING OFFICER

Enhancing core lab capabilities

Myriad genetics®

Healthcare providers (HCPs) with a better perception of Myriad Genetics - reflecting recent developments in accessibility, transparency and experience

Change in opinion about Myriad Genetics among HCPs compared to previous year



SOURCE: : Brand Equity Research 2023. Q14 (N1 in May/Dec 2022). Still thinking about these companies, how has your opinion of each company changed over the past year? Base: Respondents aware of and asked about each brand: Myriad (283)

Reasons why HCP's opinion of Myriad Genetics has improved over the past year

Expanded test profiles

"They have a variety of tests that cover not only Women's Health, but diseases specific to Primary Care."

"They're expanding their testing options and sharing their data."

Improved customer support

"They are innovative, easy to communicate with, and responsive to me."

"Customer support has improved over the past year."

Data transparency

"Being more transparent with their data."

"They've offered to make more of their data available to the public."

Quicker turnaround

"Quicker to provide results and more comprehensive services over the past 2-3 years."

Operational highlights fueling our growth

Team Engagement

Great Place To Work® Certified MAY 2023-MAY 2024 USA ™

FORTUNE BEST WORKPLACES IN HEALTH CARE™ 2023

86%

Of our team rate Myriad as a **"Great Place To Work"**

9.6%

Employee turnover, approximately half of what it was in 2021

Market Perception

67-73%

Net Promoter Score among current Myriad providers ordering across our testing portfolio

+1300 bps

Favorable consideration among providers aware of our efforts to share data with ClinVar*



Efficiency & Speed

5.5 days

Rapid turn-around times critical for patients making time-sensitive care decisions**

17%

YOY reduction in COGS per test scaling with growth, quality and regulatory requirements***

+14%

YOY sales productivity increase with structural optimization, automation and accelerating marketing demand

Revenue Cycle

+$40M

Increase in collections from 2021 – mid-2023 with fully automated revenue cycle platform

+55%

increase in prior authorization team productivity to scale with sustained high-volume growth

* SOURCE: 2022 survey conducted by Edelman HCP ETM Pulse 2022. Next time you need to recommend testing to a patient, how likely are you to consider recommending testing from the following company(s) assuming they provide the type of testing your patient needs, and you have the opportunity to choose? December 2022 Base: HCPs who were not aware of the Clinvar Announcement (n=65) / HCPs who were aware of the Clinvar Announcement (n=114)

** as of July 31, 2023

*** Excluding contribution from SneakPeak Early Gender DNA test

End-to-end technology transformation

Patient & Provider Engagement

- myGeneHistory
- Myriad.com overhaul
- Intuitive patient and provider portals

Test Ordering & Order Management

- Cost estimation and direct pay options for patients
- EMR integration for large accounts
- Ordering portals for smaller clinics

Laboratory Processing

- Next-gen sequencing platforms
- Advanced “lights out” robotic automation
- Automated variant curation pipeline

Results Delivery

- Personalized, graphical patient report
- Medical Management Tool for actionable results
- Bi-directional EMR w/ variant data

Reimbursement

- Automated revenue cycle management
- Advanced analytics platform

$50M+ Investment

Improving customer engagement, reduce friction, and enhance speed and efficiency

Myriad genetics®

$80M investment made over last two years in upgrading and automating labs, tech platforms and test processes

Laboratory Processing

WORKSTREAMS

Assay Enhancement

New features for current product

FOCUS AREAS

Advanced Sequencing

- MyChoice
- Foresight
- Prequel

Migrate to Whole Exome

- MyRisk

Real Estate

Modernize & streamline real estate portfolio

Build world-class labs

- **New** S. San Francisco innovation center
- **New** Salt Lake City lab for high-volume operations
- **New** San Diego lab
- Mental Health lab renovation In Mason

Automation

Automated backbone for lab operations

Reduce costs, enable scale

- MyRisk
- Foresight
- Future assays on advanced sequencing platforms

Innovation

New differentiated product offerings

Develop new products

- FirstGene
- Foresight panel expansion
- MRD

Myriad genetics®

Labs of the future program advancements

Highlights

On-track executing against our strategy

- New facilities opened Q2/Q3 of 2023
- Shift to next-generation sequencing nearly complete
- Phase 1 next-generation automation expected in Q1 ‘24

Benefits

- Streamlined workflows to deliver fast turnaround times
- Increased capability to innovate
- Backbone for advanced data capabilities
- Approximately **$12M** annual savings expected starting in 2025 from more efficient, centralized lab operations

Laboratory Processing

65k square feet | **Advanced R&D** incubate new technologies

Walter Gilbert Innovation Center
SOUTH SAN FRANCISCO

235k square feet | **Scale** for high volume products

Myriad Genetics Headquarters and Central Lab Operations
SALT LAKE CITY

Execution plan supported by significant investment

Laboratory Processing



$80M*
investment in modern labs

$12M
annual savings expected starting in 2025

* >85% of investment is estimated to be capitalizable expense

Myriad genetics®

Investments in structural change to improve the patient and provider experience, reduce costs, and improve reimbursement

Order management | Reimbursement

Unified, skilled team

- One organization: payer markets, revenue cycle, authorization, customer service
- Rapid identification of key friction points with providers and patients

Frictionless automated workflows

- Unified Order Management
  - Redefining Customer Service team, processes and tools
  - Single system across all businesses for customer information, order details
  - Automated communication with patients and providers
- Revenue Cycle Platform
  - Automated engagement to improve billing accuracy, reducing no-pays

Order Management

A Leading Salesforce Order Management platform

Reimbursement

Automated revenue cycle management
Advanced analytics platform

Myriad genetics®

Dale Muzzey Ph.D.

CHIEF SCIENTIFIC OFFICER

What's next

Myriad genetics®

Overall R&D strategy

Increase access—via **innovation**, **product development**, and **evidence generation**—to life-changing diagnostics that align with our core business goals

Active pipeline to better serve patients and providers

Women's Health

FirstGene™
Multiple prenatal screen

What is It?
Integrated assay for NIPS + carrier screen + fetal recessive status + feto-maternal blood compatibility on a single blood draw on one person

Key advantages
- Faster turnaround time
- 3x lower cost of goods
- Established reimbursement

Foresight™
Expanded carrier screen

What is It?
Pioneering expanded carrier screen that uses NGS to find pathogenic variants underlying recessive disease.

Key advantages
- Merged couple reporting
- Fully automated lab workflow drives low COGS

Oncology

Precise™ Tumor
Robust tumor profiling & therapy selection

What is It?
Pan-cancer comprehensive genomic profiling test using Illumina TruSight Oncology 500; may serve as first-line offering

Key Advantages
- Panel size ~2x size (500 genes) of lead competitor; uses both DNA/RNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

Precise™ Liquid
Robust tumor profiling & therapy selection

What is It?
Comprehensive genomic profiling test; may serve as first-line offering or as reflex if solid tumor is insufficient

Key Advantages
- Panel size ~2x size (500 genes) of lead competitor; uses DNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

Precise™ MRD
Minimal residual disease monitoring

What is It?
Monitoring test based on whole genome sequencing to deeply interrogate tumor, detect recurrence earlier and help guide treatment decisions

Key Advantages
- Targets 10x variants
- Known path to reimbursement

Sampling of key projects in flight



Efficiency gains through integration on whole-exome platform

Exome Platform



Platform upgrades to Foresight improve financials and enable product enhancement

Expanded Carrier Screening



Recently completed platform updates above unlock the following:

- Lower COGS
- Lower OPEX
- Harmonized workflows across products
- Easier to increase content

Foresight Universal Plus: Designed to meet anticipated medical-society guidelines

Expanded Carrier Screening



Transformative prenatal screen running multiple tests at once

FirstGene

Current PROBLEMS with prenatal genetic screening

Providers don't have enough time to talk about genetics

Only **50% utilization** of carrier screening



Only **30% of fathers** get screened when mother is a carrier

Low gross margins on **NIPS** and **ECS**

New SOLUTION

FirstGene™

Multiple Prenatal Screen



- Easier for providers to administer integrated offering
- No need to screen the father
- Estimated 30-40% higher gross margins compared to Foresight or Prequel alone

Myriad genetics®

Exemplary performance of FirstGene for fetal status nearing that of established prenatal screening

FirstGene

FirstGene Validation Study started!

(publication forthcoming)

384-sample Verification Study conducted in preparation for Validation Study

		SENSITIVITY	SPECIFICITY	PPV	NPV
Non-invasive Prenatal Screening	Aneuploidy (trisomies, SCAs, µdeletions)	**100%** (85.4%-100%)	**99.8%** (99.3%-100%)	**93.5%** (77.2%-98.9%)	**100%** (99.6%-100%)
Carrier Screening	Recessive variants in pregnant person	**99.9%** (99.7%-99.9%)	**100%** (99.99%-100%)	**100%** (99.96%-100%)	**99.97%** (99.9%-99.99%)
NEW! **Fetal recessive status**	Recessive variants in fetus	**99.6%** (98.8%-99.9%)	**98.8%** (97.8%-99.4%)	**98.3%** (97.0%-99.2%)	**99.7%** (99.1%-99.9%)
NEW! **Blood compatibility**	Rhesus D Antigen*	**100%** (2.5%-100%)	**100%** (2.5%-100%)	**100%** (2.5%-100%)	**100%** (2.5%-100%)

* Samples with confirmed Rhesus D (RhD) antigen status largely saved for Validation Study rather than use in Verification Study

Myriad genetics®

Before getting to MRD… an important update to our comprehensive genomic profiling offering

Precise Tumor/Liquid

Precise™ Tumor

Molecular Profile Test

Precise™ Liquid

Molecular Profile Test

- Both solid and liquid assays test >500 genes; solid test includes RNA analysis to detect fusions
- Precise Liquid can serve as stand-alone product for certain indications and reflex for cases where solid tumor sample is insufficient or low-quality
- Underlying panel utilized in **>75 peer-reviewed manuscripts**, including clinical validation studies

Myriad genetics®

High-definition MRD:
Differentiation built upon existing competencies



Precise Minimal Residual Disease (MRD)

- Higher sensitivity in more tumors (10x lower tumor fraction)
- 100x More of the genome explored
- 30x More sites
- Earlier detection of recurrence

Myriad genetics®

High-Definition MRD enables better treatment decisions

Precise Minimal Residual Disease (MRD)



Myriad genetics®

Excellent performance of high-definition MRD across tumor types



Precise Minimal Residual Disease (MRD)

- ~100% sensitivity at 0.01% tumor fraction, the limit of detection of a 16-site assay
- Can handily achieve limit of detection that is **5x-10x lower** than 16-site assay
- Requires **2x less tissue** than exome-based MRD offerings
- Further improvements integrated since these experiments

Myriad genetics®

Myriad and MD Anderson: Partnering to advance renal cell carcinoma care

Precise Minimal Residual Disease (MRD)

Precise™ MRD

Minimal Residual Disease Monitoring

- Top 10 cancer with ~82,000 newly diagnosed patients annually[1]
- High rates of recurrence among treated patients[2]
- Using MRD analysis to stratify patients and adjust medical management for more tolerable treatment options



Myriad genetics

Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response

June 12, 2023 08:00 ET| Source: Myriad Genetics, Inc. Follow

SALT LAKE CITY, June 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced an agreement with The University of Texas MD Anderson Cancer Center to

Study design

Testing 120 patients with recurrent RCC to assess clinical validity on Radiation + MRD

Why we're excited

Test cohort is larger than other studies submitted to MolDx for reimbursement

1. Data from American Cancer Society
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. *N Engl J Med* 1996; 335:865-875, Newmark JR, Newmark GM, Epstein JI, Marshall FF. Solitary late recurrence of renal cell carcinoma. *Urology* 1994; 43:725-728

Myriad and Memorial Sloan Kettering: Partnering to advance breast cancer care

Precise Minimal Residual Disease (MRD)



Myriad genetics

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

Research will use Myriad's high-definition MRD testing platform based on whole-genome sequencing

SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the use of minimal residual disease (MRD) testing in breast cancer. The research project will use Myriad's MRD testing platform, a tumor-informed high-definition assay that uses whole-genome sequencing to achieve high sensitivity and specificity for circulating tumor DNA (ctDNA).

Myriad is working together with Pedram Razavi, MD, PhD, a breast medical oncologist and Director of Liquid Biopsy & Genomics at MSK Global Biomarker Development Program. The MSK research team will investigate the use of MRD testing for patients in two breast cancer cohorts. The first will be in a metastatic patient population treated with CDK4/6 inhibitors and will evaluate the ability of MRD testing to predict treatment response. The second will be

Study design

Two-phase study of 100 patients with metastatic breast cancer in neoadjuvant and adjuvant setting

Why we're excited

Provides another avenue for Myriad to support women with breast cancer

"We anticipate the **MRD test from Myriad will be more sensitive and specific than many other ctDNA offerings** for monitoring the response and, therefore, may more accurately identify the patients who will or will not benefit from certain therapies. Importantly, some of these patients may go undetected on a less-sensitive MRD test."

Dr. Pedram Razavi,
Director of Liquid Biopsy & Genomics
Memorial Sloan Kettering Cancer Center

High-definition MRD: Key milestones

Precise Minimal Residual Disease (MRD)

2023

Launch Research-Use-Only (RUO) test

Partner on retrospective clinical validation
Work with leading cancer centers eager to use HD-MRD

Begin prospective clinical validity study
Three institutions onboarded; patient enrollment underway

2024

Offer HD-MRD for biopharma partners

Publish clinical validity studies
Retrospective longitudinal cohorts; one per indication

Submit for reimbursement to CMS
Show non-inferiority to currently covered tumor-informed tests

Commence clinical-utility study
Focus on provider utilization and patient outcomes

Scale laboratory operations
Low-touch, high-capacity, and high-quality with low COGS

2025

Launch Lab Developed Test (LDT)

Continue scaling laboratory operations
Low-touch, high-capacity, and high-quality with low COGS

Katie Johansen Taber Ph.D.

VP, CLINICAL PRODUCT RESEARCH & PARTNERSHIPS

Closer look at clinical programs and real-world evidence

Myriad genetics®

Establishing the evidence: A robust study and publication pipeline



Olopade et al, ASCO 2023
Dyer et al., Psych Congress 2023

FirstGene™ Multiple Prenatal Screen	Analytical validation study expected to be submitted by EOY ‘23
MyRisk® Hereditary Cancer Test	MyRisk with RiskScore ancestry-specific performance presented as podium at ASCO ‘23
Prolaris® Prostate Cancer Prognostic Test	Manuscript demonstrating value of Absolute Risk Reduction ready for submission
GeneSight® Mental Health Medication Test	Meta-analysis showed that access to GeneSight improved Major Depressive Disorder (MDD) response and remission rates

Real-world analysis of GeneSight shows decrease in hospitalizations

Study background

Compare deidentified healthcare claims among >20,000 patients receiving GeneSight

Assess changes in healthcare utilization before and after GeneSight

Phase I: Preliminary results

In the 180 days after GeneSight

DECREASED total hospitalizations by more than 25%

DECREASED psychiatric hospitalizations by more than 35%

No change in non-psychiatric hospitalizations

Additional data and detail to be included in upcoming manuscript

Next phase of study will include additional control groups and economic analyses

Manuscript in preparation
This study used data from the Optum Labs Data Warehouse, composed of de-identified administrative claims data for both commercially insured and Medicare Advantage enrollees. The claims data were linked on a de-identified basis with PGx test results.

Amplify drives 100% positive predictive value for 22q11.2 microdeletion

Prequel's positive predictive value for 22q11.2 microdeletion is **100%**, nearly double that of the leading competitor (52.6%).

	Prequel with Amplify*	Competitor offering (Dar et al, 2022)
Total cohort	**379,428**	**18,289**
Average fetal fraction in screen-positive cases	**22.7%**	**9.8%**
Positive predictive value	**100%** (CI 84.6%-100%)	**52.6%** (CI 28.9%-75.6%)

*Manuscript in preparation



Positive Predictive Value for 22q11.2 Microdeletion

"NIPS for 22q11.2 Deletion Syndrome Should Be Offered to All Patients"

American College of Medical Genetics and Genomics (Dungan et al, 2022)

*Manuscript in prep

Myriad genetics®

Building the required clinical evidence for Precise MRD

Indication	Study Types	Total Patients	Statuses
Breast (x4)		910	Enrolling, contracted, proposal
Renal (x3)		370	Running samples, contracting
Ovarian (x3)		720	Proposal
Multicancer		1000	Contracting
Other (x4)		>200	Contracting, Proposal

Myriad Prospective
Investigator-Initiated Prospective
Retrospective Collaboration
Prospective Interventional

3,200 patients

>20,000 timepoints

6+ indications

Myriad genetics®

MRD in breast cancer: Aggressive evidence generation

MONITOR-Breast

Study Design
Multi-site, Prospective, Observational

Target enrollment
650 patients in 3 groups:
HR+/HER2-, HER2+, Triple-negative

Sample collection at diagnosis, neoadjuvant treatment, surgery, post-surgery, adjuvant treatment, and after treatment

Status
3 sites actively enrolling, 7-10 additional sites in contracting

Neoadjuvant Monitoring



Adjuvant and Surveillance Monitoring



Bryan Riggsbee

CHIEF FINANCIAL OFFICER

Delivering shareholder value

Myriad genetics®

Momentum reflected in diversified volume growth



Figures in thousands

LTM[2] volume growth (YOY) across breadth of product offerings:

- Genesight: +27%
- Hereditary cancer: +16%
- Prolaris: +15%
- Prenatal[1]: +6%

Volume growth driven by:

- Commercial execution across current provider base; winning new business
- Improving provider perceptions
- Operational execution (e.g. lower turnaround times)
- Shifts in competitive landscape across select markets

1. Excluding contribution from SneakPeek Early Gender DNA test and divested businesses
2. Last twelve months as of June 30, 2023

Significant opportunity from revenue cycle management, payer engagement, and increased advocacy

Growing awareness and understanding of the value of genetic testing

- April 2022 OIG report on denials of prior authorization requests by Medicare Advantage plans thus hindering access to medically necessary care
- Increasing number of state biomarker laws enacted; engage payers and laboratory coalitions to ensure medical policies align

Expanding payer coverage

- Medical association guideline expansion for Foresight® carrier screen (awaiting)
- A number of Medicaid programs have priced, and begun paying for GeneSight® mental health medication test as of Q2 ‘23

Revenue cycle management capabilities

High ROI automation and analytics:

- Over $40 million improvement in cash collections since ’21
- +55% increase in prior authorization team productivity*

* Time period reflects CY 2021 - CY 2022

Scalable administrative support services

Advanced regulatory, reimbursement, and revenue cycle capabilities

Addressing the challenge of non-payment

Zero Pays: Result from **claims that were denied** by insurance and **patient did not provide any payment** for tests we've already processed through the laboratory

Claim Denials:
most common reasons fall into three categories

Harder to solve → Solvable with process & tools

Medical Necessity / Experimental	Authorization	Documentation / Medical Records
• Product not covered for anyone • Product is covered, but patient does not meet medical policy	• Failed to obtain prior authorization • Provider failed to obtain authorization • Authorization denied	• Missing records from provider • Provider records did not sufficiently support medical necessity

Focused efforts to drive near-term improvement in no-pay rate

Focus on the ground game

Payor compliance to current guidelines

01 State biomarker laws leading to new coverage opportunities

02 Bolster “go-to-market” messaging and targeting for *GeneSight*

Process improvements

Revenue cycle operations

01 Accelerate large-scale EMR integrations to mitigate issues with missing data

02 Deploy Unified Order Management to reduce friction for Billing

03 AI-enhanced insights to rapidly surface and resolve emerging payment hot spots

04 Optimize customer journey for Direct Pay for those who don’t meet guidelines or don’t have coverage

Augment the pre-auth team

Hire and add robotic processing (RPA)

01 Invest in added team members to keep up with double-digit growth and associated increased authorizations

02 Add RPA to off-load repetitive tasks

Estimated **+$40M** revenue opportunity in 2024 - 2026

Myriad genetics®

Accelerating growth expected through prudent investment strategy

Potential path to $1 billion+ in 2026



1. Excluding contribution from SneakPeek Early Gender DNA test and divested businesses
2. Last twelve months as of June 30, 2023. Excluding contribution from SneakPeek Early Gender DNA test, divested business, and out-of-period adjustments.
3. 2023 revenue reflects the mid-point of current revenue guidance range of between $730M - $750M

LTM[2] revenue growth of 10% driven broadly across product offerings:

- Prolaris: +20%
- Genesight: +18%
- Prenatal[1]: +13%
- Hereditary cancer: +6%

Expect 10%+ total revenue growth across portfolio, including HCT growing mid-single digits

Expect annual revenue growth to be driven by current core portfolio with potential upside beginning in '25 driven by the commercial launch of FirstGene and Precise MRD

Opportunity for adjusted gross margin expansion through 2026

Potential gross margin expansion

Gross margin[1, 3]



1. Excluding contribution from divested businesses
2. 2023 revenue reflects the mid-point of current revenue guidance range of between $730M - $750M
3. 2026 non-GAAP gross margin begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of $1 million, and non-cash amortization associated with acquisitions of $1 million.

Current gross margins at upper end of specialty lab industry range

Gross margins through 2026 are expected to benefit from:

- Accelerating volume growth
- Product mix
- Lab transition to advanced automation
- Revenue Cycle Management progress

Cost of Goods Sold (COGS) consists of approx. 30% headcount, 40% supplies, and 30% overhead. Opportunity for fixed cost leverage and cost savings in materials

SG&A operating leverage through 2026

Current salesforce of 650+ FTEs is appropriately sized per business unit

Sales headcount, by business unit

(% of total salesforce FTEs)

Women's Health	40%
Oncology	34%
Pharmacogenomics	26%

SG&A targets

~1000
basis points lower in 2026

Targeting 2026 SG&A to be ~1000 basis points lower than 2023 SG&A as a percentage of revenue.

+5-6%
annual growth

Disciplined spend in SG&A; target SG&A expense growth of approx. 5% annually, with modest headcount additions

Myriad genetics®

Potential expansion of adjusted operating income driven by elevated revenue growth and focus on cost structure

Target at least **$100 million** in adjusted operating income in 2026, or 10% of total revenue

Adjusted operating income expansion through 2026 driven by generating:

- 10%+ annual revenue growth due to strong test volume growth
- Expanding gross margins
- 5-6% annual adjusted opex growth



*2026 adjusted operating income target begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $46.0 million, non-cash amortization associated with acquisitions of approximately $43.0 million and special items such as costs related to transformation initiatives of approximately $4.0 million.

Reaffirm 2023 revenue and non-GAAP financial guidance

All figures in millions, except per share amounts

	2023 FINANCIAL GUIDANCE	2023 COMMENTS	2024 - 2026 COMMENTARY	ADDITIONAL COMMENTS
Total revenue	**$730 - $750**	2023 annual growth between 8% - 11% over 2022.	**10%+ CAGR**	Target total revenue of over $1 billion in 2026. This revenue target includes modest contribution from planned new products and no contribution from future M&A.
Gross margin %	**68% - 70%**	GM expected to fluctuate in any quarter given seasonality.	**70%+**	GM expected to fluctuate in any quarter given product mix, pricing trends and seasonality.
Adjusted operating expenses*	**$535 - $555**		**5-6% CAGR**	Balance ongoing investment in R&D with ongoing cost controls in SG&A.
Adjusted EPS*	**$(0.36) - $(0.24)**	Adjusted EPS is expected to reach positive adjusted profitability and adjusted operating cash flow in Q4 '23.	**Positive adjusted operating income and adjusted cash flow**	Target adjusted operating income of approximately $100 million in 2026**, or 10% of total revenue in 2026. Adjusted operating cash flow is expected to be in-line with adjusted operating income trend.

Assumes currency rates as of September 19, 2023

* Fiscal year 2023 non-GAAP guidance begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $40 million, non-cash amortization associated with acquisitions of approximately $43 million and special items such as costs related to transformation initiatives of approximately $24 million, legal settlement costs of approximately $80 million, and tax adjustments of approximately $8 million.

** 2026 adjusted operating income target begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $46.0 million, non-cash amortization associated with acquisitions of approximately $43.0 million and special items such as costs related to transformation initiatives of approximately $4.0 million.

Myriad genetics®

Capital structure and positive adjusted cash flow expected in 2024 and beyond

Adjusted operating cash flow



Total Capital Expenditures



- Positive adjusted operating cash flow in Q4 ’23; through 2026, adjusted operating cash flow** is expected to trend in-line with adjusted operating income
- CapEx spend in 2024 and beyond is expected to be approx $5 - $6 million a quarter
- $90 million asset-based credit facility: Plan to expand to $115M which is expected to increase availability by $10 million*
- Target $111 million in total available cash and cash equivalents and availability under credit facility at year end 2023

* The Company plans to increase the size of the ABL facility by $25 million to $115 million by the end of 2023, which is expected to increase availability under the ABL facility from $23.5 million to $33.5 million.

** Adjusted operating cash flow is a Non-GAAP measure. See the Appendix to this presentation for the definition.

Myriad genetics®

Paul J. Diaz

PRESIDENT AND CHIEF EXECUTIVE OFFICER

Closing thoughts

Myriad genetics®

Q&A

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months ended June 30, 2023 and 2022

(unaudited data in millions, except per share amounts)

	Three months ended June 30,		Six months ended June 30,	
	2023	2022	2023	2022
Adjusted Gross Margin				
GAAP Gross Profit [1]	$ 125.7	$ 129.6	$ 247.7	$ 246.5
Equity compensation	0.4	0.2	0.7	0.5
Acquisition - amortization of intangible assets	0.3	–	0.6	–
Transformation initiatives	0.2	–	0.2	–
Adjusted Gross Profit	$ 126.6	$ 129.8	$ 249.2	$ 247.0
Adjusted Gross Margin	69.0%	72.4%	68.3%	71.8%

(1) Consists of total revenues less cost of testing from the Condensed Consolidated Statements of Operations.

	Three months ended June 30,		Six months ended June 30,	
	2023	2022	2023	2022
Adjusted Operating Expenses				
GAAP Operating Expenses [1]	$ 239.4	$ 147.4	$ 413.6	$ 289.9
Acquisition - amortization of intangible assets	(10.3)	(10.1)	(20.6)	(20.3)
Goodwill and long-lived asset impairment charges	–	–	–	(10.7)
Equity compensation	(10.8)	(9.9)	(17.9)	(19.7)
Transformation initiatives	(6.2)	(3.7)	(17.8)	(7.7)
Legal charges, net of insurance reimbursement	(77.9)	1.6	(78.2)	12.9
Other adjustments	(0.8)	–	(1.2)	0.9
Adjusted Operating Expenses	$ 133.4	$ 125.3	$ 277.9	$ 245.3

(1) Consists of research and development expense, selling, general, and administrative expense, and goodwill and long-lived asset impairment charges from the Condensed Consolidated Statements of Operations.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months ended June 30, 2023 and 2022

(unaudited data in millions, except per share amounts)

	Three months ended June 30,		Six months ended June 30,	
	2023	2022	2023	2022
Adjusted Operating Income (Loss)				
GAAP Operating Loss	$ (113.7)	$ (17.8)	$ (165.9)	$ (43.4)
Acquisition - amortization of intangible assets	10.7	10.1	21.3	20.3
Goodwill and long-lived asset impairment charges	–	–	–	10.7
Equity compensation	11.1	10.1	18.5	20.2
Transformation initiatives	6.4	3.7	18.0	7.7
Legal charges, net of insurance reimbursement	77.9	(1.6)	78.2	(12.9)
Other adjustments	0.8	–	1.2	(0.9)
Adjusted Operating Income (Loss)	$ (6.8)	$ 4.5	$ (28.7)	$ 1.7

	Three months ended June 30,		Six months ended June 30,	
	2023	2022	2023	2022
Adjusted Net Loss [1]				
GAAP Net Loss	$ (116.1)	$ (14.1)	$ (170.8)	$ (34.6)
Acquisition - amortization of intangible assets	10.7	10.1	21.3	20.3
Goodwill and long-lived asset impairment charges	–	–	–	10.7
Equity compensation	11.1	10.1	18.5	20.2
Transformation initiatives	6.4	3.7	18.0	7.7
Legal charges, net of insurance reimbursement	77.9	(1.6)	78.2	(12.9)
Other adjustments	0.8	–	1.2	(0.9)
Tax adjustments	2.8	(4.7)	9.8	(9.8)
Adjusted Net Income (Loss)	$ (6.4)	$ 3.5	$ (23.8)	$ 0.7
Weighted average shares outstanding:				
Basic	81.7	80.4	81.5	80.3
Diluted	81.7	81.0	81.5	81.0
Adjusted Earnings Per Share				
Basic	$ (0.08)	$ 0.04	$ (0.29)	$ 0.01
Diluted	$ (0.08)	$ 0.04	$ (0.29)	$ 0.01

(1) To determine Adjusted Earnings Per Share, or adjusted EPS.

Myriad genetics®

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months ended June 30, 2023 and 2022

(unaudited data in millions, except per share amounts)

	Three months ended June 30,		Six months ended June 30,	
	2023	2022	2023	2022
Cash flow from operations	$ (0.9)	$ (49.7)	$ (34.1)	$ (96.2)
Transformation initiatives	6.4	3.7	12.3	7.7
Legal charges, net of insurance reimbursement	0.4	47.0	2.2	49.9
Other adjustments	—	—	0.4	—
Adjusted operating cash flow	$ 5.9	$ 1.0	$ (19.2)	$ (38.6)
Capital expenditures	(18.8)	(6.7)	(42.3)	(13.0)
Adjusted free cash flow[1]	$ (12.9)	$ (5.7)	$ (61.5)	$ (51.6)

(1) The company has revised its Adjusted Free Cash Flow metric in the quarter ended June 30, 2022 to exclude the tax impact, if any, associated with non-GAAP adjustments.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months ended June 30, 2023 and 2022

(unaudited data in millions, except per share amounts)

Following is a description of the adjustments made to GAAP financial measures:

- Acquisition – amortization of intangible assets – represents recurring amortization charges resulting from the acquisition of intangible assets.
- Goodwill and long-lived asset impairment charges – impairment charges on long-lived assets and goodwill.
- Equity compensation – non-cash equity-based compensation provided to Myriad Genetics employees and directors.
- Transformation initiatives – transitory costs such as consulting and professional fees related to transformation initiatives, additional rent as a result of the build-out of the company's new laboratories in Salt Lake City, Utah and in South San Francisco, California, while maintaining its current laboratories in those locations, re-location costs of equipment to new laboratories, severance costs, and accelerated depreciation in connection with the company's decision to cease the use of its former corporate headquarters in Salt Lake City, Utah. With respect to the adjusted free cash flow reconciliation, the cash flow effect of transformation initiatives excludes non-cash items such as accelerated depreciation.
- Legal charges, net of insurance reimbursement – one-time legal expenses, net of insurance reimbursement. With respect to the adjusted free cash flow reconciliation, the cash flow effect includes cash paid for settlements in the related period.
- Other adjustments – other one-time non-recurring expenses including consulting and professional fees related to prior year acquisitions, changes in the fair value of contingent consideration related to acquisitions from prior years and reclassifications of cumulative translation adjustments to income upon liquidation of an investment in a foreign entity.
- Tax adjustments – tax expense/(benefit) due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United States. A valuation allowance of $37.2 million was not recognized for non-GAAP purposes given the company's historical and forecasted positive earnings performance.

[1] Change of estimates may include both positive and negative adjustments primarily driven by changes in the estimated transaction price due to contractual adjustments, actual cash collections, and obtaining updated information from payors and patients that was unknown at the time revenue was recognized.